SBH
MDGL icon

Segall Bryant & Hamill’s Madrigal Pharmaceuticals MDGL Stock Holding History

Segall Bryant & Hamill’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7M Sell
31,870
-1,650
-5% -$788K 0.24% 157
2025
Q4 		$19.5M Buy
33,520
+11,030
+49% +$5.63M 0.26% 134
2025
Q3 		$10.3M Buy
+22,490
New +$8.39M 0.14% 232

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Segall Bryant & Hamill's MDGL Position: Q1 2026 in Review

Segall Bryant & Hamill reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.9% in Q1 2026, selling an estimated $788K and leaving 31,870 shares worth $16.7M. The position accounts for 0.24% of the portfolio, ranked #157.

Segall Bryant & Hamill first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. The position peaked at $19.5M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Segall Bryant & Hamill held 31,870 shares of Madrigal Pharmaceuticals worth $16.7M as of Q1 2026.
  • Segall Bryant & Hamill sold 1,650 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $788K.
  • Madrigal Pharmaceuticals made up 0.24% of Segall Bryant & Hamill's portfolio in Q1 2026, its #157 holding.
  • Segall Bryant & Hamill first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Segall Bryant & Hamill's Madrigal Pharmaceuticals position peaked at $19.5M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.